Migraine is one of the most prevalent and disabling conditions worldwide. Treatment of migraine can involve both acute and preventive interventions. Patients with frequent headache mayrequire both approaches. Acute treatment is aimed at aborting the headache attack, whereas preventive treatment is geared toward reducing the frequency and severity of attacks.
Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center / Matteo E.; Favoni V.; Pascazio A.; Pensato U.; Benini M.; Asioli G.M.; Merli E.; Calabro C.; Cortelli P.; Pierangeli G.; Cevoli S.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - STAMPA. - 41:Suppl 2(2020), pp. 483-484. [10.1007/s10072-020-04667-0]
Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center
Matteo E.;Favoni V.;Pensato U.;Benini M.;Asioli G. M.;Cortelli P.;Pierangeli G.;
2020
Abstract
Migraine is one of the most prevalent and disabling conditions worldwide. Treatment of migraine can involve both acute and preventive interventions. Patients with frequent headache mayrequire both approaches. Acute treatment is aimed at aborting the headache attack, whereas preventive treatment is geared toward reducing the frequency and severity of attacks.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
